Stockreport

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Lixte Biotechnology Holdings, Inc.  (LIXT) 
NASDAQ:AMEX Investor Relations: lixte.com/investor_information_02.php
PDF -- Three Clinical Trials Currently Underway for Treating Ovarian, Lung and Sarcoma Cancers -- PASADENA, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnolo [Read more]